Individuals with migraine may be at an increased risk for heart attacks, strokes, blood clots, and irregular heart rates, according to a recent study. Although the connection of migraine to the risk of heart problems is strongest in the first year after diagnosis, it can last for as long as 20 years. “Accumulating evidence supports that migraine should be considered as an important risk factor for most cardiovascular diseases in both men and women,” lead researcher Kasper Adelborg, MD told HealthDay.

By Dr. James Banks, National Headache Foundation Board Member This is the second part of a series related to CGRP. In the first part of the series, Dr. James Banks looks at the basics of CGRP and how it works.

Where are CGRP agents currently in the trial process and what are the early results?

The four companies with the most advanced research on the CGRP antagonists are, in alphabetical order, Alder, Amgen, Eli Lilly, and Teva. Amgen (in conjunction with Novartis) is currently involved in research on an oral CGRP antagonist. At www.headaches.org and www.clinicaltrials.gov, you’ll find a listing of where, who and what is being studied.